Extension Study of Participants From SPG302-ALS-001

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-08-31

Target enrollment:

Participant gender:

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)

PHASE2

Spinogenix